kinexus antibody microarray Search Results


phospho antibody microarrays  (Kinexus Bioinformatics Corporation)
86
Kinexus Bioinformatics Corporation phospho antibody microarrays
a , Schematic representation of ex-vivo erythropoiesis protocol to generate isogenic WT and CD44-null cRBC from primary human CD34+ HSPCs, followed by Kinexus phosphoantibody <t>microarrays.</t> b , Western blot of NUAK1 Thr211 phosphorylation in whole cell lysates from WT and CD44-null mature cRBCs (day 21) +/-EBA-175 stimulation. c , Western blot of NUAK1 Thr211 in RBC supernatant fractions from uninfected (uRBC) and P. falciparum -infected RBCs (iRBC). d , Western blot of NUAK1 expression in primary human CD34+ HSPC-derived erythroblasts at indicated dates of ex-vivo differentiation.
Phospho Antibody Microarrays, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kinexus+antibody+microarray/antibody+microarrays+phospho/bio_rxiv__2025__10__30__685469-23-29-33
Average 86 stars, based on 1 article reviews
phospho antibody microarrays - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
kinexus antibody microarray profiling  (Kinexus Bioinformatics Corporation)
86
Kinexus Bioinformatics Corporation kinexus antibody microarray profiling
a , Schematic representation of ex-vivo erythropoiesis protocol to generate isogenic WT and CD44-null cRBC from primary human CD34+ HSPCs, followed by Kinexus phosphoantibody <t>microarrays.</t> b , Western blot of NUAK1 Thr211 phosphorylation in whole cell lysates from WT and CD44-null mature cRBCs (day 21) +/-EBA-175 stimulation. c , Western blot of NUAK1 Thr211 in RBC supernatant fractions from uninfected (uRBC) and P. falciparum -infected RBCs (iRBC). d , Western blot of NUAK1 expression in primary human CD34+ HSPC-derived erythroblasts at indicated dates of ex-vivo differentiation.
Kinexus Antibody Microarray Profiling, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kinexus+antibody+microarray/antibody+kinexus+microarray+profiling/10__1042_slash_cs20258127-60-1-1
Average 86 stars, based on 1 article reviews
kinexus antibody microarray profiling - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
kam 1325 antibody microarray chips  (Kinexus Bioinformatics Corporation)
86
Kinexus Bioinformatics Corporation kam 1325 antibody microarray chips
a , Schematic representation of ex-vivo erythropoiesis protocol to generate isogenic WT and CD44-null cRBC from primary human CD34+ HSPCs, followed by Kinexus phosphoantibody <t>microarrays.</t> b , Western blot of NUAK1 Thr211 phosphorylation in whole cell lysates from WT and CD44-null mature cRBCs (day 21) +/-EBA-175 stimulation. c , Western blot of NUAK1 Thr211 in RBC supernatant fractions from uninfected (uRBC) and P. falciparum -infected RBCs (iRBC). d , Western blot of NUAK1 expression in primary human CD34+ HSPC-derived erythroblasts at indicated dates of ex-vivo differentiation.
Kam 1325 Antibody Microarray Chips, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kinexus+antibody+microarray/1325+antibody+chips+kam+microarray/pm39368789-85-15-19
Average 86 stars, based on 1 article reviews
kam 1325 antibody microarray chips - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
antibody microarray  (Kinexus Bioinformatics Corporation)
86
Kinexus Bioinformatics Corporation antibody microarray
( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific <t>microarray,</t> containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.
Antibody Microarray, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kinexus+antibody+microarray/antibody+microarray/pmc13043088-153-35-46
Average 86 stars, based on 1 article reviews
antibody microarray - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
kam 850 antibody microarray  (Kinexus Bioinformatics Corporation)
86
Kinexus Bioinformatics Corporation kam 850 antibody microarray
( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific <t>microarray,</t> containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.
Kam 850 Antibody Microarray, supplied by Kinexus Bioinformatics Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kinexus+antibody+microarray/850+antibody+kam+microarray/10__4236_slash_cm__2015__62011-52-14-17
Average 86 stars, based on 1 article reviews
kam 850 antibody microarray - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


a , Schematic representation of ex-vivo erythropoiesis protocol to generate isogenic WT and CD44-null cRBC from primary human CD34+ HSPCs, followed by Kinexus phosphoantibody microarrays. b , Western blot of NUAK1 Thr211 phosphorylation in whole cell lysates from WT and CD44-null mature cRBCs (day 21) +/-EBA-175 stimulation. c , Western blot of NUAK1 Thr211 in RBC supernatant fractions from uninfected (uRBC) and P. falciparum -infected RBCs (iRBC). d , Western blot of NUAK1 expression in primary human CD34+ HSPC-derived erythroblasts at indicated dates of ex-vivo differentiation.

Journal: bioRxiv

Article Title: Plasmodium falciparum exploits NUAK1 to establish infection in human erythrocytes

doi: 10.1101/2025.10.30.685469

Figure Lengend Snippet: a , Schematic representation of ex-vivo erythropoiesis protocol to generate isogenic WT and CD44-null cRBC from primary human CD34+ HSPCs, followed by Kinexus phosphoantibody microarrays. b , Western blot of NUAK1 Thr211 phosphorylation in whole cell lysates from WT and CD44-null mature cRBCs (day 21) +/-EBA-175 stimulation. c , Western blot of NUAK1 Thr211 in RBC supernatant fractions from uninfected (uRBC) and P. falciparum -infected RBCs (iRBC). d , Western blot of NUAK1 expression in primary human CD34+ HSPC-derived erythroblasts at indicated dates of ex-vivo differentiation.

Article Snippet: To investigate the CD44-dependent signaling induced by EBA-175, we generated isogenic wild-type (WT) or CD44-null cultured red blood cells (cRBCs) from primary human hematopoietic stem/progenitor cells (HSPCs) and used phospho-antibody microarrays produced by Kinexus ( ).

Techniques: Ex Vivo, Western Blot, Phospho-proteomics, Infection, Expressing, Derivative Assay

( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific microarray, containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.

Journal: JCI Insight

Article Title: Targeting PI3K γ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1

doi: 10.1172/jci.insight.198846

Figure Lengend Snippet: ( A ) Experimental workflow used for phosphoproteomic analysis of F508del-CFBE41o- cells treated with control peptide (CP) or PI3Kγ MP (25 μM, 30 minutes). A phospho-specific microarray, containing 875 phosphosite-specific and 451 pan-specific antibodies, was used. Thirty-six proteins showing phosphorylation changes exceeding ±60% compared with the control (expressed as percentage CFC, i.e., percentage fold-change compared with control) were selected for downstream analysis. ( B and C ) Panther Gene Ontology (GO) slim-term enrichment analysis of proteins with altered phosphorylation after PI3Kγ MP treatment. Significantly enriched GO terms (FDR < 0.05) were categorized under ( B ) biological processes and ( C ) cellular components. ( D ) Reactome pathway enrichment analysis of differentially phosphorylated proteins after PI3Kγ MP treatment. Lines represent the top 20 pathways; x axis shows the –log 10 (FDR). Color intensity reflects fold enrichment, and circle size indicates the number of proteins; color intensity (yellow to red) indicates increasing fold enrichment. The full phospho-array protein list served as background reference. ( E ) Proteins with CFC greater than 60% (green) or less than −60% (red). A CFC of 100% corresponds to a 2-fold increase in signal intensity after PI3Kγ MP treatment relative to CP.

Article Snippet: After treatment with 25 μM PI3Kγ MP or an equimolar amount of CP for 30 minutes, F508del-CFBE41o- cells were lysed as described above, and protein samples were frozen at –80°C before being subjected to an antibody microarray (KAM-1325 array) and data analysis, which was performed at Kinexus.

Techniques: Control, Microarray, Phospho-proteomics